Public Services and Procurement Canada has signed agreements with seven companies to secure access to seven COVID-19 vaccine candidates

November 19, 2020

The Government of Canada is committed to delivering safe and effective vaccines to Canadians once they are authorized. Directed by the best available science, and recognizing that the evidence base is evolving, we have been negotiating access to the most promising vaccine candidates.

To date, Public Services and Procurement Canada has signed agreements with seven companies to secure access to seven COVID-19 vaccine candidates, including:

• Medicago, which will supply up to 76 million doses of its virus-like particle vaccine candidate.
• Astrazeneca, which will supply up to 20 million doses of its viral vector vaccine candidate, AZD1222.
• Sanofi and GlaxoSmithKline, which will supply up to 72 million of doses of their protein subunit vaccine candidate.
• Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate, Ad26.COV2.S.
• Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate, NVX-CoV2373.
• Pfizer, which will supply up to 76 million doses of its mRNA-based vaccine candidate, BNT162.
• Moderna, which will supply up to 56 million doses of its mRNA-based vaccine candidate, mRNA-1273.

These agreements combined give Canada access to up to 414 million doses of COVID-19 vaccine candidates.

Precise delivery timelines vary across candidates and will depend on clinical trials and Health Canada authorization of the vaccine candidate. Our intent is to provide access to an approved, safe and effective vaccine at the earliest possible moment.